Cl-Pharm-IBS-ML-2026

The purpose of this study is to identify distinct subgroups (phenotypes) of Irritable Bowel Syndrome (IBS) patients. While traditional IBS classification relies mainly on bowel habits, this research uses a multidimensional questionnaire to capture clinical symptoms, psychological factors, diet triggers, sleep quality, and digital behaviors. By applying advanced machine learning algorithms to these patient-reported outcomes, the study aims to uncover hidden patterns that can help customize future treatments and improve patient care.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

IBS

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Participants aged 18 years or older.
Formal physician-confirmed diagnosis of Irritable Bowel Syndrome (IBS).
Ability to access and complete the digital multidimensional questionnaire.
Willingness to provide digital informed consent.

Exclusion criteria

Presence of organic gastrointestinal diseases (e.g., Inflammatory Bowel Disease, celiac disease, or colorectal cancer).
Presence of alarm/red flag symptoms (e.g., nocturnal symptoms waking the patient).
Incomplete or inconsistent questionnaire responses.

Treatment and study plan

Questionnaire and Physical Exam

Other

ONLINE QUESTIONNAIRE

Primary outcomes

Distinct patient subgroups (phenotypes) identified through unsupervised machine learning clustering algorithms.

Time frame: At the time of questionnaire completion (Baseline)

Interested in participating?

Not yet recruiting

Trial opening soon.

Get Notified

Sponsors and collaborators

Lead sponsor

Tanta University

Other

Registry information

Official study title

Machine Learning-Based Phenotyping of IBS Patients Using Multidimensional Patient-Reported Outcomes

Important dates

Study start: 2026
Primary completion: 2027
Study completion: 2027
First posted: Sep 9, 2026
Registry last updated: Sep 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not yet recruiting